Simple jQuery Dropdowns
Please use this identifier to cite or link to this item: http://repository.li.mahidol.ac.th/dspace/handle/123456789/61755
Title: The global burden of chronic urticaria for the patient and society*
Authors: M. Gonçalo
A. Gimenéz-Arnau
M. Al-Ahmad
M. Ben-Shoshan
J. A. Bernstein
L. F. Ensina
D. Fomina
C. A. Galvàn
K. Godse
C. Grattan
M. Hide
C. H. Katelaris
M. Khoshkhui
E. Kocatürk
K. Kulthanan
I. Medina
I. Nasr
J. Peter
P. Staubach
L. Wang
K. Weller
M. Maurer
Hiroshima University Graduate School of Biomedical and Health Sciences
University of Cape Town Lung Institute
Royal Hospital
Instituto Nacional de Salud del Nino, Lima
Pirogov Russian National Research Medical University (RNRMU)
Kuwait University
Universidade de Coimbra, Faculdade de Medicina
Centre Universitaire de Santé McGill, Hôpital de Montreal Pour Enfants
Charité – Universitätsmedizin Berlin
Universitat Autònoma de Barcelona
Klinikum der Johannes-Gutenberg-Universität und Fachbereich Medizin
Sun Yat-Sen University
Western Sydney University
University of Cincinnati College of Medicine
Universidade Federal de Sao Paulo
Faculty of Medicine Siriraj Hospital, Mahidol University
Sechenov First Moscow State Medical University
Guy's Hospital
Koç Üniversitesi
Mashhad University of Medical Sciences
Centro Médico Vitae
Keywords: Medicine
Issue Date: 1-Feb-2021
Citation: British Journal of Dermatology. Vol.184, No.2 (2021), 226-236
Abstract: © 2020 British Association of Dermatologists Chronic urticaria (CU) affects about 1% of the world population of all ages, mostly young and middle-aged women. It usually lasts for several years (> 1 year in 25–75% of patients) and often takes > 1 year before effective management is implemented. It presents as chronic spontaneous urticaria (CSU), chronic inducible urticaria (CIndU) or both in the same person. More than 25% of cases are resistant to H1-antihistamines, even at higher doses, and third- and fourth-line therapies (omalizumab and ciclosporin) control the disease only in two-thirds of H1-antihistamine-resistant patients. Here we review the impact of CU on different aspects of patients’ quality of life and the burden of this chronic disease for the patient and society. CU may have a strong impact on health-related quality of life (HRQoL), particularly when CSU is associated with angio-oedema and/or CIndU (Dermatology Life Quality Index > 10 in 30% of patients). Comorbidities, such as anxiety and depression, which are present in more than 30% of patients with CSU, compound HRQoL impairment. Severe pruritus and the unpredictable occurrence of weals and angio-oedema are responsible for sleep disorders; sexual dysfunction; limitations on daily life, work and sports activities; interfering with life within the family and in society; and patients’ performance at school and work (6% absenteeism and 25% presenteeism). Apart from treatment costs, with annual values between 900 and 2400 purchasing power parity dollars (PPP$) in Europe and the USA, CU is associated with a high consumption of medical resources and other indirect costs, which may reach a total annual cost of PPP$ 15 550.
URI: http://repository.li.mahidol.ac.th/dspace/handle/123456789/61755
metadata.dc.identifier.url: https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85096658120&origin=inward
ISSN: 13652133
00070963
Appears in Collections:Scopus 2021

Files in This Item:
There are no files associated with this item.


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.